Bio-Rad cuts 2025 outlook as Q1 sales fall 4.2% to $585.4 million
Bio-Rad reported first-quarter 2025 net sales of $585.4 million, down 4.2% from a year earlier, and GAAP net income of $64.0 million, down from $383.9 million, when large investment gains boosted results. The company also lowered its full-year 2025 outlook, cutting its non-GAAP operating margin estimate to 10.0% to 12.0% from 13.0% to 13.5% and revising revenue growth to a range of a 1.0% decline to 1.5% growth. The lower outlook signals weaker expected profitability and growth for 2025.
Key points
- Q1 2025 net sales were $585.4 million, down 4.2% from $610.8 million; currency-neutral sales fell 1.5%, led by Life Science.
- Q1 2025 GAAP net income was $64.0 million, or $2.29 per diluted share, versus $383.9 million, or $13.45, in Q1 2024; non-GAAP diluted EPS was $2.54 versus $2.30.
- Full-year 2025 non-GAAP currency-neutral revenue is now expected to range from a 1.0% decline to 1.5% growth, down from a prior estimate of 1.5% to 3.5% growth.
- Estimated full-year 2025 non-GAAP operating margin was cut to 10.0% to 12.0%, from a prior expectation of 13.0% to 13.5%.
The filing
Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 01, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.